United States Patent 10,835,515: Scope, Claims, and Patent Landscape for Crystalline Form I Dosage Forms and Prostate Cancer Use
United States Patent 10,835,515 is directed to oral solid dosage forms (tablet or capsule) containing crystalline Form I of a specific small molecule, defined by an X-ray powder diffraction (XRPD) peak set, and a prostate cancer treatment method using that dosage form. The claims use form-specific XRPD characterization as the key limiting feature and extend the protection from solid-state material to formulated oral products and therapeutic use.
What does US 10,835,515 claim in plain scope terms?
1) What is protected: crystalline Form I of a single defined compound
The independent claim requires the active ingredient to be:
- Crystalline Form I of
N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (labeled “I”).
The claim then requires that Form I is identified by an XRPD pattern with characteristic peaks at:
- about 8.5, 10.4, 16.6, 16.9, and 24.3 degrees 2-theta.
Claim 2 adds a second peak set (additional characteristic peaks) at:
- about 9.7, 15.9, 19.2, 21.8, and 25.5 degrees 2-theta.
This architecture means the patent protection is anchored to specific crystal form identity rather than chemical equivalence alone.
2) Where the protection applies: oral tablets and capsules
Claim 1 covers:
- pharmaceutical dosage form in the form of a tablet or capsule for oral administration,
- comprising the crystalline Form I material plus pharmaceutical excipient(s).
So the claim is not limited to bulk crystalline powder alone. It covers formulated oral solids.
3) How it is used: prostate cancer treatment method
Claim 3 covers:
- method for the treatment of prostate cancer,
- by administering a therapeutically effective amount of the dosage form of claim 1 or 2.
The therapeutic claim is therefore dependent on the same crystalline Form I dosage form limitation.
How tight is the claim construction around the crystalline form?
XRPD peak sets are the gating limitation
The independent claim’s novelty and enforceability typically hinge on whether an accused product can be shown to contain the claimed crystalline Form I, as defined by the XRPD characteristic peaks.
Claim 1 imposes a specific baseline set:
- about 8.5, 10.4, 16.6, 16.9, 24.3 (2-theta degrees)
Claim 2 adds further characteristics:
- about 9.7, 15.9, 19.2, 21.8, 25.5 (2-theta degrees)
Because the language uses “comprising characteristic peaks at about …”, infringement arguments can turn on whether the XRPD spectrum of the accused material shows the required peaks within acceptable measurement tolerances and whether the accused material is the same crystalline form or a mixture.
Dependent claim strategy
Claim 2 does two things:
- It narrows the XRPD signature further, adding more peaks.
- It creates a second infringement “hook” if a product matches the expanded set.
Practically, enforcement often uses the independent claim first (baseline peaks) and then the dependent claim as a tighter fit if the spectrum supports it.
Claim-by-claim scope mapping
Claim 1 (independent): oral tablet/capsule + crystalline Form I + baseline XRPD peaks
Covers:
- Oral tablet or capsule
- Containing:
- crystalline Form I of compound I
- characterized by XRPD peaks at ~8.5, 10.4, 16.6, 16.9, 24.3
- Includes pharmaceutical excipient
Not required (based on claim text):
- No specified excipient type, amount, or dissolution profile
- No specified manufacturing process
- No dose strength or treatment schedule
Implication for scope:
This claim has broad formulation latitude while remaining crystal-form specific.
Claim 2 (dependent): crystalline Form I + expanded XRPD peaks
Adds:
- additional XRPD peaks at ~9.7, 15.9, 19.2, 21.8, 25.5
Implication for scope:
This is a narrower version of claim 1, useful where XRPD testing provides a fuller fingerprint.
Claim 3 (dependent method): prostate cancer treatment using claim 1/2 dosage forms
Covers:
- Administering a therapeutically effective amount
- Of the dosage form defined in claim 1 or 2
- For prostate cancer
Not required in the method text:
- staging (localized vs metastatic)
- combination partners
- patient subtype
- line of therapy
Implication for scope:
The method claim is broad on clinical framing but constrained by the product limitation (dosage form defined by Form I).
What would fall inside versus outside the literal claim boundaries?
Likely inside (based strictly on claim language)
- An oral tablet or capsule containing the compound in crystalline Form I that shows the baseline XRPD peaks of claim 1.
- An oral tablet/capsule containing Form I that also exhibits the additional peaks of claim 2.
- A prostate cancer treatment regimen using those same formulations (claim 3).
Likely outside
- Oral dosage forms using a different solid form (e.g., Form II, amorphous material, solvates/hydrates) even if the chemical compound is the same.
- Products where XRPD does not show the claimed peak set as “characteristic peaks.”
- Dosage forms not in tablet/capsule oral formats (e.g., powders, injectables, films) because the claim is limited to “tablet or capsule for oral administration.”
Edge cases that become claim-fact issues
- Mixed crystalline phases: if Form I is present, XRPD may show the required peaks plus additional peaks. The claim uses “comprising characteristic peaks,” which can support mixtures if Form I peaks are present.
- Instrument/sample variability: peak positions use “about,” but the XRPD gating remains central.
Patent landscape: how to think about “space” around this claim set
1) Crystalline form patents usually cluster around XRPD fingerprints
A patent with XRPD-defined crystalline Form I typically sits in a family landscape that includes:
- prior art disclosure of the compound (often as a free base or salts),
- discovery and characterization of multiple solid forms (Form I, Form II, amorphous),
- formulation patents or use patents tied to these forms.
In that common architecture, a competitor avoids infringement by:
- using a different solid form not matching the XRPD signature, or
- using a crystalline form with different characteristic peaks, or
- changing the dosage format outside “tablet or capsule.”
2) The dependent method claim expands enforcement to clinical use
Even if a competitor formulates the same crystal form, the method claim can create leverage if marketing or physician use aligns with prostate cancer indications and “therapeutically effective amount.”
3) Real-world defenses and workarounds often target the crystalline form
Because the independent claim is extremely specific to XRPD peaks, the most direct design-around is:
- produce the same chemical but as a different crystalline form or amorphous phase,
- ensure the XRPD profile lacks the required “characteristic peaks” window.
Where this patent likely sits in a broader prosecution strategy (based on claim drafting)
The claim set is characteristic of a solid-state expansion strategy:
- material claim is effectively embedded in the dosage claim via XRPD definition,
- formulation is broadly allowed (excipient unspecified),
- indication is limited (prostate cancer) via a dependent method claim.
This structure is consistent with maximizing enforceability across:
- product form (tablet/capsule),
- physical form (crystalline Form I),
- therapeutic use (prostate cancer).
Key landscape risks for an entrant (generic or new formulation)
Risk 1: XRPD fingerprint matching
If an entrant uses crystalline Form I that matches the claimed XRPD peaks, the tablet/capsule formulation and prostate cancer method become high-risk.
Risk 2: proof and infringement testing
XRPD testing will likely be central in any dispute because the claims define Form I through XRPD peak location. The scope is therefore sensitive to:
- sample preparation,
- measurement parameters,
- peak selection criteria and tolerance.
Risk 3: label/indication alignment
Even if a product contains crystalline Form I, a method claim can become a focal point if the product is promoted or used for prostate cancer.
Key Takeaways
- US 10,835,515 protects oral tablet or capsule dosage forms containing crystalline Form I of a single specified compound, where Form I is defined by XRPD characteristic peaks at ~8.5, 10.4, 16.6, 16.9, 24.3 (claim 1) and further peaks at ~9.7, 15.9, 19.2, 21.8, 25.5 (claim 2).
- The patent extends to a prostate cancer treatment method (claim 3) using the same dosage forms.
- The enforceable boundary is primarily solid-state identity (XRPD Form I) rather than formulation composition or process.
- Design-arounds most often target crystal form (different XRPD fingerprint) and sometimes dosage format (non-tablet/capsule oral).
FAQs
1) Does the patent cover the pure crystalline Form I material?
The independent claim is drafted to cover dosage forms (tablet/capsule) comprising the crystalline Form I. It does not, on its face, claim bulk crystalline Form I alone.
2) Are the excipients limited?
No. Claim 1 requires “a pharmaceutical excipient” but does not specify excipient type or quantities.
3) What is the role of XRPD in these claims?
XRPD peak sets define whether the material qualifies as the claimed crystalline Form I, and thus whether the dosage form and method fall within the claims.
4) What does the prostate cancer claim add?
Claim 3 adds an indication-limited method: administering a therapeutically effective amount of the claim 1 or 2 dosage form for prostate cancer.
5) What is the most direct design-around?
Use a different solid form whose XRPD profile does not meet the claimed characteristic peak sets for Form I, or change the oral format away from tablet/capsule.
References
[1] United States Patent 10,835,515 (claims as provided in prompt text).
